Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 9612345...102030...Last »

Kallyope, Novo Nordisk Team Up To Tackle Obesity

New York-based Kallyope and Danish company Novo Nordisk signed a research collaboration and option deal to discover novel therapeutics to treat obesity and diabetes.

Read More »

Trump administration puts skimpy health insurance plans in place

The Trump administration issued a finalized rule that will enable millions of Americans to buy skimpy health insurance plans that do not comply with key Obamacare coverage requirements.

Read More »

Roche pays $2.4 billion for rest of cancer expert Foundation Medicine

Roche is paying $2.4 billion to buy the rest of Foundation Medicine, raising the Swiss drugmaker’s bet on the U.S. genomic profiling group’s ability to personalize cancer care.

Read More »

Kentucky sues Walgreens Boots Alliance

Kentucky’s attorney general sued Walgreens Boots Alliance Inc., accusing the company of playing a role in propagating an opioid epidemic in the state.

Read More »

J&J accepts $2.1 billion offer for LifeScan unit

Johnson & Johnson has accepted private equity firm Platinum Equity’s $2.1 billion buyout offer for the company’s LifeScan unit.

Read More »

Novartis Pays Regenxbio $100 Million for Gene Therapy Technology Under AveXis License Agreement

Rockville, Md.-based REGENXBIO snagged $100 million from Novartis under its license agreement with gene-therapy company AveXis, which the Swiss company acquired for $8.7 billion earlier in 2018.

Read More »

Melinta Therapeutics: $123 Million in Public Offering

New Haven, Conn.-based Melinta Therapeutics snagged $123 million in a public offering of 22,000,000 shares of its common stock.

Read More »

Translate Bio and Sanofi Ink Potential $850 Million mRNA Vaccine Development Deal

Translate Bio, headquartered in Lexington, Massachusetts, and Paris-based Sanofi are teaming up to develop five vaccines.

Read More »

Biotech’s Soon-Shiong hiring bankers for Nant cancer drug IPO

Billionaire Patrick Soon-Shiong plans to take an experimental cancer treatment company public during 2018 and has begun hiring bankers, the biotechnology entrepreneur told Reuters.

Read More »

French Company Ipsen to Move U.S. Headquarters to Boston

Ipsen plans to relocate the French company’s U.S. operations from New Jersey to Kendall Square in Cambridge, Mass.

Read More »

Bill and Melinda Gates Foundation Spins Out a Nonprofit Biotech Company

The Bill & Melinda Gates Foundation spun off a biotech company called The Bill & Melinda Gates Medical Research Institute (MRI) located in Boston.

Read More »

Biogen Options Stroke Drug from TMS

Biogen, headquartered in Cambridge, Massachusetts, signed an exclusive option deal with Tokyo-based TMS for TMS-007 and backup compounds.

Read More »

J&J Announces Binding Offer from Fortive to Acquire Advanced Sterilization Products

Johnson & Johnson received a binding offer to sell its Advanced Sterilization Products (ASP) business to Fortive Corporation. The deal is valued at $2.8 billion.

Read More »

Biogen Pays Alkermes $50 Million Milestone for MS Drug

Alkermes, headquartered in Dublin, Ireland, received a $50 million milestone payment from Cambridge, Massachusetts-based Biogen.

Read More »

Axovant Licenses Parkinson’s Disease Gene Therapy

Axovant Sciences announced that the biotech start-up licensed exclusive worldwide rights to OXB-102, now dubbed AXO-Lenti-PD, from Oxford BioMedica.

Read More »

Pfizer to Expand Venture Investing with $600 Million Commitment to Pfizer Ventures

Pfizer Inc. announced plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture investment vehicle.

Read More »

Syneos Health Consulting Releases 10th Annual Biopharmaceutical Dealmakers Survey

The tenth annual Dealmakers’ Intentions Study from Syneos Health Consulting, an industry-leading consulting firm specializing in the biopharmaceutical industry, concludes that the dealmaking environment will continue to accelerate with buyers becoming more selective in ensuring they have the most appropriate assets and corresponding deals in place.

Read More »

Nimbus Therapeutics Raises Another $65 Million from Lilly, Bill Gates, Pfizer and Others

Nimbus Therapeutics, headquartered in Cambridge, Massachusetts, raised an additional $65 million in financing. Early investors participated, including Atlas Venture, SR One, Lilly Ventures, Bill Gates, Pfizer Venture Investments, Lightstone Ventures and Schrodinger.

Read More »

Shuttered, Closed, Halted and Killed: Biopharma Companies End Programs

Here is a look at some notable programs that have been shuttered by biopharmaceutical companies during 2018.

Read More »

Allergan plans sales of women’s health, infectious disease units

Allergan plans to sell off both businesses as the company’s CEO works to end a steep slide in the drugmaker’s share price.

Read More »

Page 1 of 9612345...102030...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2018 Focus: Agency Profiles, Manny Awards and Annual Review


Ad Right Bottom

Main Navigation